Budesonide/formoterol Maintenance and Reliever Therapy (MART) versus budesonide/formoterol plus as-needed salbutamol in children 6-11 years with asthma: A Randomized Control Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 98
- 试验地点
- 1
研究概览
简要总结
Asthma is the most common chronic respiratory condition of childhood worldwide. Current treatment recommended by guidelines in persistent asthma is fixed-dose inhaled corticosteroids (ICS) or ICS/LABA (long acting beta agonist) combination with as needed short acting beta-agonist (SABA). A novel approach is budesonide/formoterol Maintenance and Reliever Therapy (MART) using single inhaler, without requirement of SABA. Studies have shown MART is more effective at reducing exacerbations and improving daily asthma control than the same maintenance dose of budesonide/formoterol plus as needed SABA. Lacunae in existing literature- Paucity in existing literature comparing Budesonide/formoterol as MART versus Budesonide/formoterol plus as needed salbutamol as controller options in children 6-11 years with asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 6.00 Year(s) 至 11.00 Year(s)（—）
- 性别
- All
入选标准
- •GINA step 3 asthma.
排除标准
- •Chronic lung disease ~ BPD Congenital thoracic malformations Airway malacia Mucociliary dysfunction- Cystic fibrosis, primary ciliary dyskinesia History of recent exacerbation requiring oral/IM/IV corticosteroid in last 4 weeks.
研究者
Sathya Srivatsav
AIIMS Jodhpur